Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SolidAct Baricitinib in Immunocompromised Hospitalised COVID-19 Patients
2022-500385-99-00Phase 3Completed
- Sponsor
- Oslo University Hospital
- Start
- Apr 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Baricitinib + standard of care with Placebo + standard of care (2 arms). Started Apr 2022; status: completed.
02
Drugs
baricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-500385-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500385-99-00.